Skip to main content
SpringerLink
Log in

Current Systemic Therapy Options for Head and Neck Cancers

  • Chapter
  • First Online:
Radiation Therapy for Head and Neck Cancers

  • 1817 Accesses

Abstract

Head and neck cancers refer to heterogeneous group of tumors extending from the lips to the lower esophagus. Squamous cell cancer is the most common histologic variant, accounting approximately 90–95 % of head and neck cancers. The incidence of head and neck cancer still continues to increase worldwide with approximately half million cases per year [1]. In the United States, it is estimated about 55.070 new head and neck cancers will occur in 2014 which account for up to 3 % of cancer cases [2]. In 2014, it is estimated that 12.000 deaths will occur from head and neck cancer in the United States. In Europe, it is estimated about 139.000 new cases of head and neck cancer per year [3]. In Europe, the 1-year survival rate was 72 %, whereas 5-year survival rate was only 42 % for head and neck cancers in adults [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CF:

Cisplatin-fluorouracil

EORTC:

European Organization for Research and Treatment Cancer

GETTEC:

French Groupe d’Etude des Tumeurs de la Tête et du Cou trial

GORTEC:

French Head and Neck Oncology Radiotherapy Group

OS:

Overall survival

PFS:

Progression-free survival

TCF:

Docetaxel-cisplatin-fluorouracil

VALCSG:

The Department of Veterans Affairs Laryngeal Cancer Study Group

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

    Article  PubMed  Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  3. Gregoire V, Lefebvre JL, Licitra L, Felip E, Group E-E-EGW (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–v186. doi:10.1093/annonc/mdq185

    Article  PubMed  Google Scholar 

  4. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M, National Comprehensive Cancer N (2013) Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11(8):917–923

    PubMed  Google Scholar 

  5. Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, Hamoir M, Machiels JP (2014) Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 40(3):390–404. doi:10.1016/j.ctrv.2013.09.007

    Article  CAS  PubMed  Google Scholar 

  6. Price KA, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13(1):35–46. doi:10.1007/s11864-011-0176-y

    Article  PubMed  Google Scholar 

  7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127. doi:10.1056/NEJMoa0802656

    Article  CAS  PubMed  Google Scholar 

  8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578. doi:10.1056/NEJMoa053422

    Article  CAS  PubMed  Google Scholar 

  9. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28. doi:10.1016/S1470-2045(09)70311-0

    Article  CAS  PubMed  Google Scholar 

  10. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F, Margarino G et al (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327(16):1115–1121. doi:10.1056/NEJM199210153271602

    Article  CAS  PubMed  Google Scholar 

  11. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88(9):583–589

    Article  CAS  PubMed  Google Scholar 

  12. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98

    Article  PubMed  Google Scholar 

  13. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208):949–955

    Article  CAS  PubMed  Google Scholar 

  14. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. doi:10.1016/j.radonc.2009.04.014

    Article  PubMed  Google Scholar 

  15. Bourhis J, Le Maitre A, Baujat B, Audry H, Pignon JP, Meta-Analysis of Chemotherapy in Head NCCG, Meta-Analysis of Radiotherapy in Carcinoma of Head NCG, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative G (2007) Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 19(3):188–194. doi:10.1097/CCO.0b013e3280f01010

    Article  PubMed  Google Scholar 

  16. Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, Eliachar I, Strome M, Van Kirk MA (1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19(7):567–575

    Article  CAS  PubMed  Google Scholar 

  17. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA (2000) Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88(4):876–883

    Article  CAS  PubMed  Google Scholar 

  18. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098. doi:10.1056/NEJMoa031317

    Article  CAS  PubMed  Google Scholar 

  19. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852. doi:10.1200/JCO.2012.43.6097

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20(8):2038–2044

    Article  CAS  PubMed  Google Scholar 

  21. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97(7):536–539. doi:10.1093/jnci/dji084

    Article  CAS  PubMed  Google Scholar 

  22. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21(4):631–637

    Article  PubMed  Google Scholar 

  23. Huncharek M, Kupelnick B (2002) Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25(3):219–223

    Article  PubMed  Google Scholar 

  24. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP, Group M-NC (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64(1):47–56. doi:10.1016/j.ijrobp.2005.06.037

    Article  CAS  PubMed  Google Scholar 

  25. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B, French Groupe d’Etude des Tumeurs de la Tete et du C (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83(12):1594–1598. doi:10.1054/bjoc.2000.1512

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, Group ETS (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704. doi:10.1056/NEJMoa071028

    Article  CAS  PubMed  Google Scholar 

  27. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, Group TAXS (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715. doi:10.1056/NEJMoa070956

    Article  CAS  PubMed  Google Scholar 

  28. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR, Group TAXS (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159. doi:10.1016/S1470-2045(10)70279-5

    Article  CAS  PubMed  Google Scholar 

  29. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101(7):498–506. doi:10.1093/jnci/djp007

    Article  CAS  PubMed  Google Scholar 

  30. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP, Meta-Analysis of Chemotherapy in H, Neck Cancer IPCG (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31(23):2854–2860. doi:10.1200/JCO.2012.47.7802

    Article  CAS  PubMed  Google Scholar 

  31. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264. doi:10.1016/S1470-2045(13)70011-1

    Article  CAS  PubMed  Google Scholar 

  32. Cohen EE, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, Mehra R, Kumar P, Ondrey FG, Seiwert TY, Villaflor VM, Haraf DJ, EE V (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, 2012 ASCO annual meeting abstracts, vol 30, No 15_suppl (May 20 Suppl), 5500

    Google Scholar 

  33. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991). N Engl J Med 324(24):1685–1690. doi:10.1056/NEJM199106133242402

  34. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88(13):890–899

    Article  CAS  PubMed  Google Scholar 

  35. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M, European Organization for R, Treatment of Cancer T (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. doi:10.1056/NEJMoa032641

    Article  CAS  PubMed  Google Scholar 

  36. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group I (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944. doi:10.1056/NEJMoa032646

    Article  PubMed  Google Scholar 

  37. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198–1205. doi:10.1016/j.ijrobp.2012.05.008

    Article  PubMed Central  PubMed  Google Scholar 

  38. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850. doi:10.1002/hed.20279

    Article  PubMed  Google Scholar 

  39. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10(2):257–263

    CAS  PubMed  Google Scholar 

  40. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10(8):1245–1251

    CAS  PubMed  Google Scholar 

  41. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology G (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23(15):3562–3567. doi:10.1200/JCO.2005.01.057

    Article  CAS  PubMed  Google Scholar 

  42. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666–2672. doi:10.1200/JCO.2005.04.8306

    Article  CAS  PubMed  Google Scholar 

  43. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6(2):701–708

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Yıldırım Beyazıt University, Faculty of Medicine, Ankara, Turkey

    Mehmet Ali Nahit Sendur MD

  2. Department of Medical Oncology, Hacettepe University, Cancer Institute, Sihhiye, Ankara, 06100, Turkey

    Sercan Aksoy MD

Authors
  1. Mehmet Ali Nahit Sendur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sercan Aksoy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sercan Aksoy MD .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Gulhane Military Medical School, Ankara, Turkey

    Murat Beyzadeoglu

  2. Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit

  3. Department of Radiation Oncology, Koc University, Faculty of Medicine, Istanbul, Turkey

    Ugur Selek

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sendur, M.A.N., Aksoy, S. (2015). Current Systemic Therapy Options for Head and Neck Cancers. In: Beyzadeoglu, M., Ozyigit, G., Selek, U. (eds) Radiation Therapy for Head and Neck Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-10413-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-10413-3_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-10412-6

  • Online ISBN: 978-3-319-10413-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation